Biotech & Programmable Life: Synthetic Biology, Gene Editing & More
Biotech & Programmable Life: Synthetic Biology, Gene Editing & More. Follow coverage across AI and emerging technology, ranked by the Polyemergence importance method.
Coherus Oncology is cutting 30% of its workforce as it narrows its clinical focus primarily onto esophageal cancer. The decision follows early-stage trial data showing strong anti-tumor activity when combining its experimental antibody tagmokitug with its approved drug Loqtorzi, prompting the company to reduce costs and extend its cash runway.
AbCellera announced it will stop developing its experimental autoimmune drug ABCL575 after completing an early-stage trial. Although the drug met its primary safety goals, the company pointed to broader industry challenges in the OX40 drug class. Several major drug developers have recently scaled back or cancelled similar programs due to safety concerns or modest clinical benefits.
The U.S. Treasury's proposed rules to restrict outbound investments in China's biopharma sector have sparked intense concern among industry leaders and legal experts. While Washington aims to protect national and economic security, critics like RA Capital's Peter Kolchinsky warn that the vague regulations—particularly around joint ventures—will blind U.S. investors, cripple domestic innovation, and inadvertently hand a competitive advantage to European and Chinese rivals.
The U.S. Department of Health and Human Services announced up to $25 million in funding for ibogaine and other rapid-acting psychotropic drugs to treat serious mental illnesses like PTSD in veterans. Led by Health Secretary Robert F. Kennedy Jr., the initiative includes research networks and clinical trial preparations, though ibogaine also carries documented risks of severe cardiac and neurological complications.
Cardiometabolic biotech Marea Therapeutics reports that its drug candidate MAR001 significantly reduced blood fat in a phase 2b study for patients with high triglycerides. The antibody lowered triglycerides by over 70% in patients with very high levels, while showing a side effect rate slightly below the placebo group. CEO Josh Lehrer notes the results are encouraging for patients facing pancreatitis and heart attack risks, with plans to advance further studies and explore potential applications in obesity.
Delix Therapeutics has secured $100 million in Series C funding to advance zalsupindole, a non-hallucinatory psychedelic therapy designed to treat major depressive disorder. Backed by Johnson & Johnson, the company plans to start a Phase 2b clinical trial in 2027.
Merck reports that its experimental drug efinopegdutide successfully treated MASH (metabolic dysfunction-associated steatohepatitis) in a mid-stage clinical trial. The drug outperformed a placebo by helping clear the liver disease in over half of the tested patients without worsening liver scarring.
Regeneron announced that its experimental monoclonal antibody, baloncibart, met its primary goal in a Phase 2 trial for postural orthostatic tachycardia syndrome, a chronic condition with no FDA-approved treatments. Patients receiving a single high dose experienced a mean drop in heart rate of 11.4 beats per minute compared to placebo, paving the way for a Phase 3 study planned for early 2027.
At the ObesityWeek 2026 conference, biopharma companies are shifting attention beyond standard GLP-1 drugs to explore new pathways like amylin modulation. Industry experts emphasize that the next generation of weight loss therapies will focus heavily on improving treatment persistence and the quality of weight reduction, particularly preserving muscle mass.
Smart ring maker Oura is acquiring telehealth startup Counsel Health, a platform previously promoted by drugmaker Eli Lilly for GLP-1 prescriptions. Experts warn this deal introduces potential conflicts of interest because patients sharing health data through Oura rings may now be treated by clinicians within the same newly-acquired ecosystem, complicating how pharmaceutical companies direct patient care.
Researchers in genomics and proteomics often struggle with choosing the right statistical methods to avoid false discoveries. A recent Nature Biotechnology Comment proposes a 2 × 2 matrix to help scientists navigate these options. This framework helps researchers match their data and study design with the most rigorous statistical procedures available.
Zura Bio has discontinued development of its experimental drug tibulizumab for hidradenitis suppurativa after a phase 2 trial missed its primary endpoint. The trial failed because the placebo group performed much better than expected, matching the drug's effectiveness. Following the news, Zura's stock plunged 72%, though the company stated it still has enough cash to fund operations through 2028.
Spruce Biosciences is spinning out its preclinical endocrinology program, including a monoclonal antibody for congenital adrenal hyperplasia, into a new entity called Adrenyx Biosciences. Backed by up to $50 million in private equity and led by Spruce's CFO, the separation allows Spruce to focus on neurological disorders while Adrenyx prioritizes endocrinology.
Boehringer Ingelheim reports that its obesity drug survodutide has successfully met its primary endpoint in a late-stage cardiovascular safety trial, showing no increased risk of major heart-related events. The company plans to submit for regulatory approval next year, positioning the therapy for patients looking to lose metabolic fat while preserving muscle, despite higher gastrointestinal side effect discontinuation rates compared to some rivals.
BioSpace reviews recent cardiovascular drug trials, noting that several late-stage failures have questioned traditional targets like IL-6 and lipoprotein(a). Despite these setbacks, successes from companies like Eli Lilly and Merck, along with upcoming late-stage data, offer hope for future treatments.
Blackstone is backing Pfizer’s bet on a monthly obesity treatment. Meanwhile, the FDA commissioner nominee Heidi Overton is facing a tight Senate vote due to concerns over past vaccine policies, and Bristol Myers Squibb is shaking up its R&D leadership.
Addex Therapeutics spinout Neurosterix secured $105 million in a Series B financing round led by RTW Investments. The company plans to use the funds to advance its oral M4-targeting candidate NTX-253 into mid-stage clinical trials for schizophrenia. Additionally, Neurosterix appointed three former Karuna Therapeutics leaders who previously worked on the newly approved schizophrenia drug Cobenfy.
Swiss biotech Windward is planning a Nasdaq IPO to raise over $200 million, primarily to fund respiratory drugs licensed from China. The company aims to advance its phase 2 and phase 3 clinical trials for asthma and chronic obstructive pulmonary disease, backed by major pharmaceutical investors including Sanofi.
Bristol Myers Squibb is combining its research and development into a single unit as the pharmaceutical giant faces impending patent expirations for its top-selling drugs. Chief Research Officer Robert Plenge will step down, with Chief Medical Officer Cristian Massacesi taking over the unified team to accelerate drug development.
In a recent podcast episode, industry experts discuss why drug shortages are worsening. They explore how combining predictive analytics with flexible manufacturing could help make essential medicines more accessible.
Biogen is preparing to release the results of twin Phase 3 studies for its lupus drug, litifilimab, in early December. This upcoming data serves as a crucial test for the research and development overhaul initiated by CEO Chris Viehbacher, carrying high stakes for the company's growth strategy.
Columnist Adam Feuerstein re-evaluates his previous prediction about biotech company Alnylam reaching a $100 billion valuation. He notes that Alnylam must successfully address its heart drug challenges to sustain its market growth and fulfill its earlier potential.
In a podcast conversation with Elad Gil, Isomorphic Labs president Max Jaderberg discusses the company's vision to shift drug discovery into a process of precision engineering through predictive AI models. Jaderberg highlights how AlphaFold's success served as a proof of concept for deep learning in biology, and predicts that compounding learnings at scale will improve clinical trial success rates and speed, potentially reducing animal testing and extending human healthspan.
An FDA analysis of gene therapy applications from 1995 to 2025 shows rapid growth in adeno-associated virus development and identifies common reasons for regulatory holds, aiming to help developers avoid pitfalls.
A former Eli Lilly sales representative has filed a lawsuit claiming she was fired after reporting that the company unlawfully promoted its diabetes medication for weight loss before receiving official regulatory approval, highlighting ongoing scrutiny within the booming obesity treatment market.
Broad kidney disease labels often hide important biological differences, which can mess up clinical trials. In a recent podcast, Dr. Ronen Schneider from Natera explains how genetic testing combined with real-world health data helps drug developers find the right patient groups. By looking at genes alongside actual patient histories, teams can design better trials, pick the right goals, and avoid hidden surprises in their studies.
PepGen's experimental drug for myotonic dystrophy type 1 achieved a record splicing correction of 46.5% in a mid-stage clinical trial, outperforming competitors and causing its stock price to nearly double. The positive safety profile and potential for higher doses offer new hope for treating this rare genetic disease.
Capricor Therapeutics saw its operating expenses surge 70% in the third quarter as it ramps up manufacturing for its upcoming Duchenne muscular dystrophy cell therapy. With an FDA decision looming, the company's San Diego facility is fully prepped for an initial launch, though past regulatory hurdles and a mixed advisory vote still cast some uncertainty over the approval.
According to Google DeepMind: Google has announced AlphaGenome 2, an AI model that predicts how DNA sequence variations impact specific human cell types and disease states. Trained on over 100 million individual cell profiles, the model identifies twice as many causal variants as its predecessor, helping scientists uncover the cellular roots of various diseases.
Faeth Therapeutics reported that its oral cancer therapy combination, called Piktor, hit key efficacy goals in a phase 2 trial for endometrial cancer. The drug achieved a 33% confirmed overall response rate, outperforming expectations and offering a pill-based alternative to injectable treatments like ADCs and chemotherapies.
Edesa Biotech has partnered with Kyorin Pharmaceutical to bring its late-stage respiratory drug to Japan in a deal worth up to $140 million. Kyorin will handle all local development and commercialization costs, while also gaining a first refusal right for other potential medical uses.
Scientific research rarely gives a simple first answer, and real progress often comes from looking beyond setbacks to find new questions. Ipsen's Chief Business Officer shares how looking past failed hypotheses in areas like rare diseases and oncology can lead to valuable new treatments through smart partnerships and acquisitions.
BioSpace is launching a weekly tracker to monitor the stock performance of U.S. biotechs that go public in 2026. After a long dry spell, biotech IPOs are finally making a comeback, but keeping an eye on how they perform after their debut is crucial for the industry.
Novartis's gene therapy Zolgensma is under FDA investigation after nine patients developed tumors. Meanwhile, the FDA requires a safety warning for all GLP-1 weight loss drugs regarding a rare vision-threatening eye condition, as the agency faces a busy month of drug decisions.
According to MIT Biological Engineering: MIT's School of Engineering is welcoming new faculty across multiple disciplines, bringing fresh perspectives to research and teaching.
The FDA's newly launched rare disease framework is facing its first major test as the agency decides whether to approve Capricor's cell therapy, deramiocel, for Duchenne muscular dystrophy. With the decision looming, the case highlights the tension between strict statistical rules and the harsh realities of treating progressive, rare conditions where slowing physical decline means preserving patient independence.
Beam Therapeutics announced that its CRISPR-based treatment for sickle cell disease successfully met the main goal in a key clinical trial. Patients achieved freedom from severe pain crises for at least 12 months, and the company plans to file for FDA approval by the end of this year.
Biotech company PepGen announced that its experimental drug showed promising early results in treating a severe muscle disorder affecting over 100,000 people. Although PepGen entered the race relatively late, this data from six patients provides a much needed boost to the field, especially after a rival drug from Novartis recently failed in late-stage trials.
According to MIT Biological Engineering: MIT researchers are leading a $53 million project funded by ARPA-H to create safer, next-generation weed killers. By using generative AI, the team aims to discover alternative molecules that protect crops while avoiding health and resistance risks.
China's government has proposed blocking the sale of specific biotech platforms to foreign entities. This move adds key technologies in biomedicine, AI, and green energy to an export blacklist, aiming to prevent technology risks and manage proper international cooperation.
The UK Biobank is teaming up with biotech companies to analyze blood samples from 80,000 people. They are building a massive immune dataset using AI and advanced tech, and separately running a brain health study to spot early signs of diseases like Alzheimer's decades before symptoms show up.
Researchers have developed a statistical framework called RNA fingerprinting to match single-cell RNA sequencing data with reference perturbation dictionaries. Published in Cell, the method uses a Bayesian probabilistic framework to accurately identify cellular responses across different cell types and datasets, helping scientists better understand complex biological mechanisms.
The FDA has approved Bayer's new drug, Sunharbo, to help prevent recurrent strokes. As the first in a novel class of medications, it targets a specific protein to block dangerous blood clots without increasing the usual risk of bleeding.
In this YC Paper Club discussion, experts explore how falling sequencing costs are transforming biology into a data-rich landscape. The speakers discuss cancer as a data problem and highlight unexpected capabilities such as in-context learning emerging in genome models without explicit training.
